Phase I/II vaccine study targeting novel HLA-A2-restricted CTL epitopes in combination with poly-ICLC in patients with recurrent malignant glioma.

摘要: 2506 Background: We conducted a phase I/II trial to evaluate the safety and immunogenicity of novel vaccination with α-type-1-polarized dendritic cells (αDC1) loaded synthetic peptides for glioma associated antigen (GAA) epitopes administration poly-ICLC in HLA-A2+ patients recurrent malignant gliomas. GAAs these are EphA2, IL-13Rα2, YKL-40 gp100. Methods: The study enrolled twenty-two glioblastoma (GBM) (n = 13), anaplastic astrocytoma 5), oligodendroglioma 3), or oligoastrocytoma 1). Half had 2nd relapse greater. Two GBM prior bevacizumab. Peptide-loaded αDC1 were injected intra/peri-nodally every two weeks 4 injections possibility boosters. 20 µg/kg was administered intramuscularly times per week 8 weeks. Immunogenicity assessed by ELISPOT, tetramer, IL-12 assays. Efficacy determined MRI according McD...